An Update on Quality Assurance and Procurement through WHO for Improving Access to Artemisinin-based Combination Treatments (ACTs) for Malaria Consistent with WHO recommendations, malaria endemic countries which are experiencing high levels of resistance to currently used antimalarial drugs such as chloroquine and sulfadoxine/pyrimethamine (SP) are changing treatment policies from monotherapies to artemisinin-based combination treatments (ACTs). This four-page update provides the latest information on these pharmaceutical developments for treating P. falciparum malaria. (28/Jul/2003) In English (10.2k)
(41.98k)
(168.09k)
Consistent with WHO recommendations, malaria endemic countries which are experiencing high levels of resistance to currently used antimalarial drugs such as chloroquine and sulfadoxine/pyrimethamine (SP) are changing treatment policies from monotherapies to artemisinin-based combination treatments (ACTs). This four-page update provides the latest information on these pharmaceutical developments for treating P. falciparum malaria. (28/Jul/2003)
